Abstract
Background. Anaemia is a common and potentially treatable co-morbidity of end-stage renal disease. We aimed to determine the prevalence of the sub-target haemoglobin (Hb) level among European children on dialysis and to identify factors associated with a low Hb level. Methods. From the European Society for Paediatric Nephrology (ESPN)/European Renal Association-European Dialysis Transplant Association (ERA-EDTA) registry, data were available on 2351 children between 1 month and 18 years of age, totalling 5546 measurements from 19 countries. Results. The mean Hb level was 10.8 g/dL (5th-95th percentiles, 7.4-13.9). Among those above 2 years of age, the mean Hb level was 10.9 g/dL (11.4% below 8.5 g/dL), while it was 10.3 g/dL among those below 2 years (11.2% below 8.0 g/dL). A total of 91.2% of the patients were on an erythropoiesis-stimulating agent (ESA). Hb levels increased with age and were higher in peritoneal dialysis compared with haemodialysis patients. Patients with congenital anomalies of the kidney and urinary tract showed the highest Hb levels, and those with cystic kidney diseases or metabolic disorders the lowest ones. Ferritin levels between 25 and 50 ng/mL were associated with the highest Hb levels. We found a weak inverse association between parathyroid hormone (PTH) and Hb. Whereas standardized blood pressure (BP) was not elevated in patients with above-target Hb, elevated systolic BP z-score was noted in those with sub-target Hb levels. Conclusions. Sub-target Hb levels remain common in children on dialysis, in spite of virtually all children being treated with ESA; although we cannot exclude under-
Introduction
Anaemia is a common feature among children with endstage renal disease (ESRD) [1] , due mainly to impaired erythropoietin synthesis by the diseased kidneys, and an absolute or functional iron deficiency [2] . Other contributing factors include inflammation, regular blood loss, vitamin deficiency, hyperparathyroidism, haemoglobinopathies, haemolysis, uraemia and medications [1] . Studies have shown that anaemia is associated with reduced survival in adolescent and adult dialysis patients [3] [4] [5] . Conversely, higher haemoglobin (Hb) values have been associated with improved health-related quality of life [6] , exercise tolerance and a reduction in cardiac index in children on dialysis [7] .
Due to a paucity of paediatric outcome data, the optimal Hb level for children on dialysis is not known. The physiological age dependence of Hb levels adds another level of complexity to paediatric anaemia management [8] . The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines [9] define anaemia as an Hb below the 5th percentile for age and gender. Recently, the 2011 UK National Institute for Clinical Excellence (NICE) Anaemia Management in chronic kidney disease (CKD) guidelines suggested a target Hb of 10-12 g/dL or 9.5-11.5 g/dL if younger than 2 years of age [10] . The Anaemia Working Group of European Renal Best Practice (ERBP) suggested a target Hb for adults with CKD between 11.0 and 12.0 g/dL, without intentionally exceeding 13.0 g/dL [11, 12] . Upper limits for target Hb are based on adult studies where a target Hb level of 14 ± 1 g/dL was associated with higher mortality in patients with cardiovascular disease and was not cost effective [13, 14] . There are no published European guidelines for the management of anaemia in children with ESRD, apart from guidelines for paediatric peritoneal dialysis (PD) patients, where a target Hb of at least 11.0 g/dL is suggested, with no upper limit specified [15] . On the other hand, recently, the US Food and Drug Administration (FDA) recommended more conservative dosing guidelines for treating Hb levels, suggesting to initiate erythropoiesis-stimulating agent (ESA) treatment only when the Hb level is <10 g/dL [16] .
The use of iron therapy and ESA is recommended in children with ESRD to achieve optimal Hb levels based on age [1, 12] . Nevertheless, anaemia remains a significant problem, with anaemia present in half of the children on chronic haemodialysis (HD) and PD in a US study [2] . The prevalence of the sub-target Hb level in children on dialysis across Europe is not well defined. We performed this study to (i) determine the prevalence of sub-target Hb levels in European children on dialysis; (ii) identify risk factors for sub-target Hb levels in this patient population; (iii) study the relationship between biochemical parameters, namely ferritin, parathyroid hormone (PTH) and albumin, and Hb levels; and (iv) determine the prevalence of the use of ESA and iron therapy among European children on dialysis.
Materials and methods
Countries collected individual data on date of birth, gender, treatment modality at the start of renal replacement therapy (RRT) and changes in RRT modality within the framework of the European Society of Paediatric Nephrology (ESPN)-European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) Registry [17] . Patients aged 18 years or under who were on dialysis between 2000 and 2009 were included in the analysis, including patients who had returned to dialysis after a transplant. In some, this was following a ( pre-emptive) transplant as first RRT as detailed in Table 1 . For the present study, only those countries that provided data on the Hb level on a substantial subset of the patients in each calendar year were included. Nineteen countries contributed to the study: Belarus Measurements from infants less than 1 month of age were excluded from the data set as Hb levels are physiologically elevated.
Serum Hb, ferritin and PTH were determined according to the local practice. We used multiple imputation for missing data on Hb, ESA use (yes/no), iron use (yes/no), ferritin and PTH based on the total data set in order to decrease selection bias as is recommended by the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. [18] . We included only those countries for analyses involving these measures in which the variable of interest was reported for some of the patients. Imputations were based on age at measurement, gender, cause of renal failure (five groups), treatment modality at the time of measurement, time on RRT, Hb level and ESA use, preceding Hb level and ESA use, and log-transformed ferritin and PTH levels in both the patients for whom the data were known, and those in whom the data were missing. We performed sensitivity analyses among the complete cases only to determine whether associations were similar when using only those with a complete data set. Following the methods published in the National High Blood Pressure Education Program (NHBPEP) Fourth report [19] , we calculated systolic and diastolic BP Z-score for each subject, thereby adjusting for age, sex and height (a -3 height z-score was used for heights ≤ a z-score of -3) [20] . Body mass index (BMI) z-score was calculated according to the Centers for Disease Control and Prevention (CDC) reference charts [21] .
We arbitrarily defined the target range of Hb as between 10.5 and 12.0 g/dL for children younger than 2 years and between 11.0 and 12.5 g/dL for children 2 years or older (Table 2) , which we based on an amalgamation of the European guidelines for children on PD [15] , the 2011 UK NICE guidelines for children with CKD [10] , the European guidelines for adults and the FDA guidelines [11] . We extended this classification to six groups namely those being severely below target, subtarget, borderline sub-target, within target range, over target and grossly over target. If a patient was not receiving ESA treatment an ESA and was over target, he was considered to be on target.
We categorized the causes of renal disease according to the ERA-EDTA coding system, adapted for children [22] , into congenital anomalies of the kidney and urinary tract (CAKUT), glomerulonephritis, cystic kidney disease, hereditary nephropathy, ischaemic renal failure, haemolytic uraemic syndrome (HUS), metabolic disorders, vasculitis, other known kidney disease, and missing or unknown kidney disease. We studied all individual causes of renal failure that were referred to in the ERA-EDTA coding system (65 different causes) to identify whether any specific causes of renal failure were at higher or lower risk of sub-target Hb levels.
Analyses
In the ESPN/ERA-EDTA registry data, both the response variable of interest (e.g. Hb level) and explanatory variables (e.g. age, treatment modality) Anaemia in children on dialysiswere measured several times in each individual. Observations of one individual over time are not independent but correlated. To calculate percentages, where patients could be in multiple groups during different measurements, every measurement was divided by the total number of measurements for that patient. In the analyses for the association of parameters on Hb levels, linear mixed model analyses were used, thereby adjusting for multiple measurements in the same patient as well as possible confounders. Both a random intercept and a random slope at a patient level were calculated based on time between the measurements. When studying the variation within an individual patient, the absolute value of the difference between two subsequent measurements, which were selected to be ½ to 1½ years apart, was calculated. In the analyses for a dichotomous outcome, such as factors related to being sub-target, receiving ESA treatment or using iron therapy, logistic mixed model analyses were used. The analysis of all individual causes of renal failure was adjusted for multiple testing by considering only P < 0.01 as statistically significant. For all other analyses, P-values of <0.05 were considered as statistically significant. All analyses were adjusted for age, gender, cause of renal failure, duration of RRT and dialysis modality and were performed in SAS 9.2.
Results

Patient characteristics
A median of two measurements was available for 2351 patients (range 1-17 per patient, just one measurement from 18.5%), thereby providing 5546 measurements. Most patients were male (56.4%), and CAKUT was the most common cause of renal failure (38.2%). Most data were provided by adolescents (aged between 13 and 18 years, 56.3%) and by patients on PD (55.0%; Table 1 ).
Hb levels and predictors of sub-target Hb levels
The mean Hb level among dialysis patients was 10.8 g/ dL, with 5th and 95th percentiles of 7.4 and 13.9g/dL, respectively. Intra-individual differences between pairs of measurements selected to be ½ to 1½ years apart averaged ±0.96 g/dL. Of those below 2 years of age, 42% of the children were within the target range, while 20.9% were borderline sub-target, 21.2% were below target and 11.2% were severely below target. Another 15.7% of the patients were slightly over target, while 3.7% were grossly over target. Among those above 2 years of age, 21.2% were borderline sub-target, 19.8% were below target, 11.4% were severely below target, 28.6% were within the target range and 16.4% were slightly over target while 2.5% were grossly over target (Figure 1) .
The mean Hb levels differed in the various subgroups (Table 3) . Hb levels increased with increasing age and were higher in PD compared with HD patients. There were no differences between males and females. Over time, there was a significant increase in the mean Hb level, independent of the countries that were included, showing an increase in the Hb level by 0.038 g/dL [95% Children who were severely below target had a mean change in Hb levels of +3.9 g/dL those below target had a mean change of +2.3 g/dL, while those being borderline below target had an increase of 1.1 g/dL. In contrast, children who were slightly over target had a mean change in Hb levels of −1.5 g/dL, and those grossly over target had a greater change of −3.4 g/dL. These were all significantly different from those who were within the target range, where median Hb levels changed by −0.55 g/dL. The estimates and the significance level did not change after adjustment for age, gender, cause of renal failure, duration between measurements or treatment modality. The Hb level during the previous measurement was the only factor related to a subsequent change in the Hb level, as age, gender, duration of RRT, cause of renal failure and dialysis modality were unrelated to change.
Relationship of Hb levels with ferritin, PTH, albumin, height and BP levels
Ferritin levels below 25 ng/mL were associated with lowest Hb levels (10.8 g/dL; Figure 2 ). The association was borderline significant (P = 0.06) and did not change after Fig. 1 . Distribution of children on dialysis who were severely below target, sub-target, within target range, over target and grossly over target in children above and below 2 years of age. In the boxes, the percentage of patients on an ESA is presented. Results presented in bold are significant, P < 0.05. The adjusted Hb levels were recalculated using the distribution of all cases. a The reference population. b Adjusted for age at measurement, gender, RRT modality, cause of renal failure and duration of RRT. 25 and 50 ng/mL were associated with the highest Hb levels (11.2 g/dL), while higher ferritin levels were associated with lower mean Hb levels (10.9 g/dL, P = 0.08). Lowest ferritin levels were associated with the highest subsequent Hb levels. Similar results were found in the complete-case analyses.
There was an inverse association between elevated PTH and Hb levels (Figure 2) , showing highest mean Hb levels among those with PTH levels below 50 pg/mL (P < 0.05). This relationship was similar in children older and younger than 2 years. PTH levels between 500 and 1000 pg/mL and above 1000 pg/mL were associated with, respectively, 0.33 g/dL (0.10-0.56, P < 0.05) and 0.55 g/ dL (0.16-0.94, P < 0.05) lower mean Hb levels when compared with PTH levels below 500 pg/mL. This relationship was also found in the complete-case analyses. Serum ferritin and PTH were independently associated with Hb levels (Figure 2) .
Hb levels strongly increased with increasing albumin levels: for each g/dL increase in albumin, Hb levels increased by 0.056 g/dL (95% CI 0.044-0.069, P < 0.05). This association remained significant after adjustment for possible confounders, was independent of the relationship between ferritin, PTH and BMI z-score with the Hb level and remained in the complete-case analyses.
Height was positively associated with Hb levels, also after adjustment for age, gender and cause of renal failure. However, growth, (change in height between two measurements) was not associated with Hb levels.
Patients with severe, mild or borderline sub-target Hb levels had significantly higher systolic BP z-scores than patients who were within the target range. Standardized BP was not elevated in patients with above-target Hb levels ( Figure 3 ).
ESA and iron use
In countries with information on ESA treatment, the vast majority of dialysis patients were prescribed ESAs (91.2% in 2008). The percentage of ESA use has been constant in the different countries since 2002. Gender, dialysis modality and age were not significantly associated with different use of ESAs both with and without adjustment for confounders. On a country level, there tended to be a small inverse association between the percentage of children who were below target and the percentage of patients on ESA treatment, with slightly more children below target among countries with a lower use of ESA. However, this relation was no longer significant after adjustment for country size. The percentage of patients on an ESA for the different Hb groups is presented in Figure 1 .
Of patients from countries with information on both iron and ESA treatment, 57.3% of the patients were prescribed iron therapy. Only 35.2% of the patients not on ESA were prescribed iron therapy, compared with 59.6% of those on ESA therapy, and this relationship between iron and ESA use remained strongly significant after adjustment for potential confounders. Age, gender and dialysis modality were not associated with the use of iron.
Cause of renal failure
When studying the cause of renal failure in more detail, patients with a kidney tumour causing renal failure had the lowest mean Hb levels (1.48 g/dL lower, 95% CI −2.0 Results suggest that the highest mean Hb levels were obtained among those dialysis patients with a ferritin level between 25 and 49 ng/mL and a PTH level under 50 pg/mL as indicated by the dark 'peak'. Both higher PTH levels, along the axis on the left to the centre, and higher ferritin levels, along the axis on the right to the centre, showed independently lower mean Hb levels, as indicated by the lighter shading. Using linear regression analyses, we adjusted for age, gender, cause of renal failure and dialysis modality. to −0.79, P = 0.004) ( Table 4) . Furthermore, patients with oxalosis or hereditary nephropathy under the age of 2 had significantly lower mean Hb levels when compared with patients with CAKUT, but this difference disappeared after adjustment for age, gender and dialysis modality. Patients with cystic kidney disease used an ESA significantly more often (93.1% versus 90.2% in those with CAKUT, P < 0.05), but received iron less often (54.7% versus 66.1% in those with CAKUT, P < 0.05). Also, patients with hereditary nephropathy under 2 years of age (37.9%) received iron less often than patients with CAKUT (66.1%, P < 0.05).
Discussion
Despite increasing awareness of the deleterious long-term effects of anaemia [1, 23] , and a small but consistent improvement in Hb levels over the observation period, subtarget Hb levels remain very common in children on dialysis. In this study, nearly half of children were below target, with nearly a 10th of the population having very low Hb levels, despite virtually all patients being prescribed ESAs. This finding is consistent with data from the USA, showing the prevalence of Hb levels below 11 g/dL between 33 and 54% of HD patients [2, [24] [25] [26] and between 31 and 70% of PD patients [2, 24] , and the presence of anaemia (including the use of ESA in defining anaemia) in 97% of paediatric Stage 5 CKD patients [27] . As in a US study [24] , ESAs were prescribed in over 90% of dialysis children.
As shown before [24, 26] , younger children had a greater likelihood of having a sub-target Hb level. While the physiological increase in Hb levels with age was accounted for in children <2 years by using a lower cut-off for defining within target Hb levels, the higher rate of sub-target Hb levels observed in the 2-to 12-year age group compared with adolescents might in part be explained by the use of a constant cut-off above 2 years. Another reason for the lower mean Hb level in young children might be related to a greater proportion of blood loss to total body blood volume during phlebotomy and/ or HD when compared with adolescents.
Assessing the causes of renal failure in more detail, we found a higher risk of sub-target Hb levels in children with renal failure due to a kidney tumour. Possible explanations might relate to the use of cytotoxic therapy or more frequent presence of bilateral nephrectomies, resulting in complete loss of endogenous erythropoietin production. Treating anaemia may therefore require higher doses of ESAs in this patient group.
We found highest Hb levels among children with ferritin levels between 25 and 50 ng/L. Low Hb levels with very low ferritin levels (<25 ng/L) are most likely explained by absolute iron deficiency. However, we were somewhat surprised that the optimal Hb level was this low as earlier studies in adult and paediatric HD patients associate an iron deficiency component to renal anaemia with ferritin levels <100 ng/mL [and transferrin saturation (TSAT) <20%] [28] . Unfortunately, we did not have sufficient number of percentage TSAT or percentage hypochromic red cell data to assess iron stores in a more detailed manner, and the sensitivity and specificity of serum ferritin as a measure of iron stores is limited. In children, very limited data on the optimal target of ferritin are available and the upper end of the desirable range of ferritin is unclear. Whereas it is usually recommended to avoid very high ferritin levels (>1000 ng/mL) which can lead to deposition of iron in tissues [12] , in this study, any serum ferritin levels over 50 ng/mL were associated with lower mean Hb levels. Less marked elevations of serum ferritin may reflect inflammatory processes, which can cause ESA-resistant anaemia [29] [30] [31] . Still, these optimal ferritin levels are lower than the current recommendation based on adult studies, which is to aim for levels between 200 and 500 ng/mL.
Another potential cause of ESA resistance is hyperparathyroidism. Potential mechanisms include a direct effect of PTH on bone marrow erythroid progenitor cells and on red cell survival through accelerated haemolysis, and an indirect effect through induction of bone marrow fibrosis [23] . Indeed, high PTH levels were independently associated with sub-target Hb levels, which has been found by others [32, 33] , but contrasts with two US studies which did not find an association [25, 34] .
Low albumin can be a marker of inflammation, malnutrition or intravascular fluid overload. Studies in adult HD Results presented in bold are significantly different after adjustment for age at measurement, gender, duration of RRT and dialysis modality, when compared with patients with CAKUT. For the specific causes of renal failure, mentioned in italics, a stronger cut-off of P < 0.01 to determine significance was used to adjust for multiple testing. For the other causes of renal failure, which were grouped, a cut-off of P < 0.05 was used. The numbers can vary per analysis as not all countries were included in all the measurements.
patients have shown an inverse correlation between ESA dose and nutritional markers [30] , and similar strong associations were found between albumin and Hb levels in adults and adolescent HD patients [25, 35, 36] . In our study, the association of Hb and serum albumin levels was independent of BMI and ferritin levels. Unfortunately, we did not have sufficient data on C-reactive protein, so we cannot completely exclude inflammation, but this still seems to suggest that fluid overload leading to haemodilution may be the most important factor causing dilution of both Hb and albumin levels. This is also supported by the observation of higher BP levels in the severely below-target patients. Furthermore, factors other than fluid overload may play a role in some patients. Tissue hypoxia caused by anaemia leads to vasodilation, which in turn causes increased sympathetic tone and arterial stiffness, leading to hypertension. It has been suggested that full normalization of Hb levels by ESA therapy would be undesirable as it might aggravate hypertension [37] . In this context, it is of note that we did not find increased BPs among patients who slightly or even grossly exceeded the Hb target range. ESA-induced hypertension might mainly occur in the initial correction phase [37] and could relate more to ESA dose than to Hb target. We could not study this in detail due to a lack of information on ESA dose, but our findings support the notion that ESA-induced hypertension is not a major issue in children on stable maintenance therapy.
During the period of observation, it is clear that attempts were made to normalize Hb levels. This was reflected by the marked increase in Hb levels among children who were severely below target and the decrease in Hb levels among those who were grossly above target, resulting in a next mean Hb level of around 11 g/dL. However, the large variability of Hb levels, with an average absolute difference of 1 g/dL between pairs of measurements illustrates the difficulty in obtaining stable Hb levels.
Our study has limitations. First, we obtained data from patients with highly variable dialysis duration. During the course of the treatment, less healthy patients were selected, as those who received a renal allograft were censored. A second limitation is the large difference in the number of measurements per patient. We adjusted for this using linear and logistic mixed model analyses, thereby taking into account within-patient variability and time between measurements. A further limitation is that information on Hb levels was not available for all children. To avoid selection bias as much as possible, we imputed missing data and used only those countries from which at least some data were reported. Despite validation of imputation, and comparison with the complete-case analyses, a full data set would have been more accurate, as there is always the possibility that patients with missing data items differ generally from those in whom complete data are available. Furthermore, data were collected as obtained locally and different laboratory measurements may be a source of centre bias. The variability in measurement methods could have affected our results. However, the error in measurements is most likely to be unrelated to the Hb, PTH, ferritin or albumin level (non-differential misclassification). This type of error leads to a dilution of any association, making it more difficult to observe associations between Hb and other factors in our study.
Unfortunately, we did not have information on ESA dosing. Therefore, we cannot exclude the possibility of relative under dosing of ESA, as recent studies have suggested that children need absolute ESA doses similar to those used in adults [38, 39] . This interpretation is likely because (i) it is common practice to dose ESA according to body weight, (ii) low Hb was observed more frequently in young children and (iii) ferritin levels did not explain the absolute Hb levels as discussed earlier.
Finally, due to the observational character of the study, we cannot claim any cause-effect relationships for the factors we found were associated with sub-target Hb levels. Nevertheless, we believe that this large-scale analysis of the European paediatric dialysis population provides useful information to generate hypotheses on how to optimize anaemia management in children with ESRD.
Conclusions
Sub-target Hb levels are still a very common problem in children on dialysis, despite virtually all children being treated with ESA. Under-dosing of ESA is not excluded. Sub-target levels are more prevalent with certain causes of renal failure and among HD patients. Very low, but also high ferritin levels are associated with lower Hb levels, as is hyperparathyroidism. When studying Hb levels in relation to BP, we did not find any evidence of ESA-induced hypertension. We did not study sub-target Hb levels in relation to outcomes and thus cannot judge whether current guidelines, which are mainly based on derivatives of studies among adults, are valid. In order to improve anaemia management, long-term outcome studies defining optimal targets for Hb in the paediatric dialysis population are needed.
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